CD40 and familial pancreatic carcinoma: Neoadjuvant CD40 agonism in pancreatic cancer resulted in an increased density of DCs and a T cell–enriched tumor microenvironment compared to historical controls treated with chemotherapy, radiation, or no neoadjuvant therapy (7).